EXO1 as a therapeutic target for Fanconi Anaemia, ZRSR2 and BRCA1-A complex deficient cancers
More about Open Access at the CrickAuthors list
Marija Maric Sandra Segura-Bayona Raviprasad Kuthethur Tohru Takaki Valerie Borel Tyler Stanage Miroslav P Ivanov Venkata Nishita Mohan Parnandi Graeme Hewitt Rhona Millar Carmen S Fonseca Harshil Patel Miriam Llorian Sopena Scott Warchal Michael Howell Arnab Ray Chaudhuri Panagiotis Kotsantis Simon BoultonAbstract
Exonuclease EXO1 performs multiple roles in DNA replication and DNA damage repair (DDR). However, EXO1 loss is well-tolerated, suggesting the existence of compensatory mechanisms that could be exploited in DDR-deficient cancers. Using CRISPR screening, we find EXO1 loss as synthetic lethal with many DDR genes somatically inactivated in cancers, including Fanconi Anaemia (FA) pathway and BRCA1-A complex genes. We also identify the spliceosome factor and tumour suppressor ZRSR2 as synthetic lethal with loss of EXO1 and show that ZRSR2-deficient cells are attenuated for FA pathway activation, exhibiting cisplatin sensitivity and radial chromosome formation. Furthermore, FA or ZRSR2 deficiencies depend on EXO1 nuclease activity and can be potentiated in combination with PARP inhibitors or ionizing radiation. Finally, we uncover dysregulated replication-coupled repair as the driver of synthetic lethality between EXO1 and FA pathway attributable to defective fork reversal, elevated replication fork speeds, post-replicative single stranded DNA exposure and DNA damage. These findings implicate EXO1 as a synthetic lethal vulnerability and promising drug target in a broad spectrum of DDR-deficient cancers unaddressed by current therapies.
Journal details
Journal
Nature Communications
Volume
16
Issue number
1
Pages
8476
Available online
Publication date
Full text links
Publisher website (DOI)
10.1038/s41467-025-63349-7
Figshare
View on figshare
Europe PubMed Central
41006228
Pubmed
41006228
Data and code
Keywords
Related topics
Type of publication
